EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Inhibition of Wnt/β‐catenin pathway overcomes therapeutic resistance to abiraterone in castration‐resistant prostate cancer

Ibrahim M Atawia, Prem P Kushwaha, Shiv Verma, Spencer Lin, Eswar Shankar, Osama Abdel-Gawad, Sanjay Gupta iD

Molecular Carcinogenesis · 2023

DOI: 10.1002/mc.23565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2023. Verfasst von Ibrahim M Atawia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Case Western Reserve University, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: U.S. Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Abiraterone acetate has been clinically approved for the treatment of patients with advanced‐stage prostate cancer. It reduces testosterone production by blocking the enzyme cytochrome P450 17 alpha‐hydroxylase. Despite improved survival outcomes with abiraterone, almost all patients develop therapeutic resistance and disease recurrence, progressing to a more aggressive and lethal phenotype. Bioinformatics analyses predicted activation of canonical Wnt/β‐catenin and involvement of stem cell plasticity in abiraterone‐resistant prostate cancer. Increased expression of androgen receptor (AR) and β‐catenin and their crosstalk causes activation of AR target genes and regulatory networks for which overcoming acquired resistance remains a major challenge. Here we show that co‐treatment with abiraterone and ICG001, a β‐catenin inhibitor, overcomes therapeutic resistance and significantly inhibited markers of stem cell and cellular proliferation in abiraterone‐resistant prostate cancer cells. Importantly, this combined treatment abrogated the association between AR and β‐catenin; diminished SOX9 expression from the complex more prominently in abiraterone‐resistant cells. In addition, combined treatment inhibited tumor growth in an in vivo abiraterone‐resistant xenograft model, blocked stemness, migration, invasion, and colony formation ability of cancer cells. This study opens new therapeutic opportunity for advanced‐stage castration‐resistant prostate cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantMaleHumansDrug Resistance, Neoplasmbeta CateninNeoplasm Recurrence, LocalReceptors, AndrogenAndrostenes

Stichwörter der Autor:innen

androgen deprivation therapyandrogen receptorcancer stem cellscastration resistant prostate cancersignaling pathways

Substanzen

beta CateninReceptors, AndrogenabirateroneAndrostenes

Autor:innen und Institutionen

  • Department of Urology, Case Western Reserve University, Cleveland, Ohio, USA.
  • Department of Urology, Menoufia University, Menoufia, Egypt.
  • University Hospitals Cleveland Medical Center, The Urology Institute, Cleveland, Ohio, USA.
  • College of Arts and Sciences, Case Western Reserve University, Cleveland, Ohio, USA.
  • Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio, USA.
  • Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.

ORCID-Profile: Sanjay Gupta

Förderung

  • U.S. Department of Defense

Zitieren

APA

Atawia, I. M., Kushwaha, P. P., Verma, S., Lin, S., Shankar, E., Abdel-Gawad, O., & Gupta, S. (2023). Inhibition of Wnt/β‐catenin pathway overcomes therapeutic resistance to abiraterone in castration‐resistant prostate cancer. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23565

Vancouver

Atawia IM, Kushwaha PP, Verma S, Lin S, Shankar E, Abdel-Gawad O, et al. Inhibition of Wnt/β‐catenin pathway overcomes therapeutic resistance to abiraterone in castration‐resistant prostate cancer. Molecular Carcinogenesis. 2023. doi:10.1002/mc.23565

BibTeX
@article{Atawia2023,
  author = {Atawia, Ibrahim M and Kushwaha, Prem P and Verma, Shiv and Lin, Spencer and Shankar, Eswar and Abdel-Gawad, Osama and Gupta, Sanjay},
  title = {Inhibition of Wnt/β‐catenin pathway overcomes therapeutic resistance to abiraterone in castration‐resistant prostate cancer},
  journal = {Molecular Carcinogenesis},
  year = {2023},
  doi = {10.1002/mc.23565}
}
Kostenlos starten →